Novavax Inc. closed 61.59% short of its 52-week high of $17.81, which the company achieved on July 26th.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated ...

Novavax Inc. closed 60.47% below its 52-week high of $17.81, which the company achieved on July 26th.

Novavax (NVAX) closed the most recent trading day at $6.61, moving -2.79% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.79% for the day. At the ...

Novavax Inc. research and ratings by Barron's. View NVAX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid ...

The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.

Novavax (NVAX) closed at $6.36 in the latest trading session, marking a -2.15% move from the prior day. This move lagged the ...